A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Detailní popis
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Admin Cugene
- Telefonní číslo: 1(781) 893-5800
- E-mail: admin@cugene.com
Studijní místa
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- Nábor
- NEXT Virginia
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Signed and dated informed consent.
- Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
- At least 1 measurable lesion according to RECIST v1.1.
- Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
- Life expectancy of ≥3 months.
- Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.
Exclusion Criteria
- Rapidly progressing disease or disease requiring urgent alternative medical intervention.
- Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
- Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
- Concurrent participation in another interventional therapeutic clinical trial.
- Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
- Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
- Unresolved clinically significant toxicities from prior anticancer therapy.
- Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
- Active or clinically significant infection except as specified in the protocol.
- Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
- Known hypersensitivity or significant allergic reaction to biologics or its components.
- Recent vaccination, except as permitted by the protocol.
- Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Sekvenční přiřazení
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Part A Dose Escalation
CUG279 will be administered at multiple ascending dose levels |
CUG279 will be administered intravenously according to the protocol |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs)
Časové okno: From the first dose up to 21 days post-dose
|
The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A. |
From the first dose up to 21 days post-dose
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Časové okno: From first dose through 90 days after the last dose
|
The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of serious adverse events (SAEs)
Časové okno: From first dose through 90 days after the last dose
|
The number and percentage of participants with SAEs will be assessed. |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in safety laboratory parameters from baseline
Časové okno: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Časové okno: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in vital signs from baseline
Časové okno: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of TEAEs leading to dose modifications
Časové okno: From the first dose through the last dose; up to 1 year
|
The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed. |
From the first dose through the last dose; up to 1 year
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Trough plasma concentrations (Ctrough) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose |
From first dose through 90 days after the last dose
|
|
Area under the concentration-time curve (AUC) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Terminal half-life (T1/2) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Systemic clearance (CL) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Volume of distribution (Vz) of CUG279
Časové okno: From first dose through 90 days after the last dose
|
The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 antibodies (ADA)
Časové okno: From first dose through 90 days after the last dose
|
Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Časové okno: From first dose through 90 days after the last dose
|
Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined |
From first dose through 90 days after the last dose
|
|
Objective response rate (ORR)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Disease control rate (DCR)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Time to response (TTR)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1 |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Duration of response (DoR)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Time from first documented CR or PR to disease progression will be determined per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Best overall response (BOR)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Progression-free survival (PFS)
Časové okno: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
Další identifikační čísla studie
- CUG279-P101
- IND 179862 (U.S. FDA IND) (Jiný identifikátor: FDA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .